Sorafenib is a multikinase inhibitor which inhibits tumor proliferation and angiogenesis by inhibiting vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, platelet-derived growth factor receptor β (PDGFRβ); FMS-like tyrosine kinase 3 (Flt-3) c-Kit protein (c-Kit), Raf and RET receptor tyrosine kinases10. The gene discussed is FLT3; the disease is neoplasm.